Chimerix, Inc.

NasdaqGM:CMRX Stock Report

Market Cap: US$79.1m

Chimerix Valuation

Is CMRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CMRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CMRX ($0.91) is trading below our estimate of fair value ($195.7)

Significantly Below Fair Value: CMRX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CMRX?

Key metric: As CMRX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CMRX. This is calculated by dividing CMRX's market cap by their current book value.
What is CMRX's PB Ratio?
PB Ratio0.6x
BookUS$135.78m
Market CapUS$79.14m

Price to Book Ratio vs Peers

How does CMRX's PB Ratio compare to its peers?

The above table shows the PB ratio for CMRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.8x
ETXP.F e-therapeutics
2.7xn/aUS$76.0m
VTGN Vistagen Therapeutics
0.7x9.2%US$70.6m
CUE Cue Biopharma
2.6x-2.1%US$69.1m
MCRB Seres Therapeutics
5.2x-17.2%US$138.5m
CMRX Chimerix
0.6x36.1%US$79.1m

Price-To-Book vs Peers: CMRX is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (2.8x).

Price to Book Ratio vs Industry

How does CMRX's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$507.04m
NKTX Nkarta
0.4x-11.5%US$176.42m
IMAB I-Mab
0.4x1.8%US$79.81m
ACET Adicet Bio
0.4x6.7%US$79.69m
CMRX 0.6xIndustry Avg. 1.8xNo. of Companies84PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CMRX is good value based on its Price-To-Book Ratio (0.6x) compared to the US Biotechs industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is CMRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CMRX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CMRX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CMRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.91
US$7.00
+666.1%
32.6%US$11.00US$5.00n/a5
Nov ’25US$0.99
US$7.00
+607.1%
32.6%US$11.00US$5.00n/a5
Oct ’25US$0.89
US$6.83
+668.0%
30.9%US$11.00US$5.00n/a6
Sep ’25US$0.93
US$6.83
+633.1%
30.9%US$11.00US$5.00n/a6
Aug ’25US$0.85
US$7.00
+718.7%
29.7%US$11.00US$5.00n/a6
Jul ’25US$0.87
US$7.00
+705.5%
29.7%US$11.00US$5.00n/a6
Jun ’25US$0.97
US$7.00
+624.0%
27.5%US$11.00US$5.00n/a7
May ’25US$0.95
US$7.00
+636.8%
27.5%US$11.00US$5.00n/a7
Apr ’25US$1.05
US$7.00
+566.7%
27.5%US$11.00US$5.00n/a7
Mar ’25US$1.17
US$7.00
+498.3%
27.5%US$11.00US$5.00n/a7
Feb ’25US$0.93
US$7.33
+687.9%
25.7%US$11.00US$5.00n/a6
Jan ’25US$0.96
US$7.33
+661.9%
25.7%US$11.00US$5.00n/a6
Dec ’24US$1.01
US$7.33
+626.1%
25.7%US$11.00US$5.00n/a6
Nov ’24US$0.96
US$7.33
+663.9%
25.7%US$11.00US$5.00US$0.996
Oct ’24US$0.96
US$7.33
+664.0%
25.7%US$11.00US$5.00US$0.896
Sep ’24US$1.08
US$7.33
+582.2%
25.7%US$11.00US$5.00US$0.936
Aug ’24US$1.19
US$7.67
+544.3%
27.8%US$11.00US$5.00US$0.856
Jul ’24US$1.21
US$7.67
+533.6%
27.8%US$11.00US$5.00US$0.876
Jun ’24US$1.39
US$7.67
+451.6%
27.8%US$11.00US$5.00US$0.976
May ’24US$1.19
US$7.80
+555.5%
29.7%US$11.00US$5.00US$0.955
Apr ’24US$1.26
US$7.80
+519.0%
29.7%US$11.00US$5.00US$1.055
Mar ’24US$1.59
US$8.00
+403.1%
26.2%US$11.00US$6.00US$1.175
Feb ’24US$1.82
US$8.00
+339.6%
26.2%US$11.00US$6.00US$0.935
Jan ’24US$1.86
US$8.00
+330.1%
26.2%US$11.00US$6.00US$0.965
Dec ’23US$2.35
US$8.00
+240.4%
26.2%US$11.00US$6.00US$1.015
Nov ’23US$1.88
US$8.00
+325.5%
26.2%US$11.00US$6.00US$0.965

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.41

7D

0.5%

1Y

17.1%

IQVIA Holdings

US$35.3b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$197.60

7D

-2.6%

1Y

-5.7%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.86

7D

-5.2%

1Y

8.0%